NCT05730712 2026-02-06Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate CancerMayo ClinicPhase 2 Completed7 enrolled
NCT00005857 2011-10-20Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone TherapyCity of Hope Medical CenterPhase 2 Completed